nach oben

Clinical Rheumatology

Erschienen in:

05.01.2020 | Original Article

Characteristics of patients with primary Sjögren’s syndrome associated interstitial lung disease and relevant features of disease progression

verfasst von: Ting Zhang, Fangfang Yuan, Li Xu, Wenjia Sun, Lei Liu, Jing Xue

Erschienen in: Clinical Rheumatology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate characteristics of patients with primary Sjögren’s syndrome (pSS)-associated interstitial lung disease (ILD) and relevant features of ILD progression.

Method

Patients with pSS were retrospectively reviewed, and pSS-ILD and pSS non-ILD were identified. Clinical data, laboratory parameters, pulmonary high-resolution CT (HRCT), and pulmonary function tests (PFTs) were collected. pSS-ILD patients were further categorized into subgroups according to HRCT patterns or PFTs.

Results

Eighty-five pSS-ILD patients and 85 pSS non-ILD patients were included. The average age at disease onset and median disease duration were significantly higher in pSS-ILD patients than those in pSS non-ILD patients (p < 0.001). Fever, xerostomia, xerophthalmia, and numbness were more frequent, and white blood cells, C reactive protein, and immunoglobulin G (IgG) levels were higher in pSS-ILD patients when compared to pSS non-ILD patients (p < 0.01). More male patients, older age at disease onset, and less frequent anti-Ro52 antibody were noted in patients with CT-usual interstitial pneumonia (UIP) pattern. In 49 patients with pSS-ILD, who repeated PFTs 6 months from the baseline, 79.6% were stable while 20.4% progressed, with ESR and CT-UIP pattern related with disease progression.

Conclusions

Patients with pSS-ILD were characterized by more frequent fever, xerophthalmia, and elevated IgG levels, while male, older age at disease onset, and less frequent anti-Ro52 antibody were related with CT-UIP pattern. ESR and CT-UIP pattern were potential predictors for ILD progression.

Key Points

• pSS-ILD patients are characterized by more frequent fever, xerophthalmia and elevated IgG.

• Anti-Ro52 antibody is less frequent in patients with CT-UIP pattern compared to non-UIP patterns.

• ESR and CT-UIP pattern are associated with pSS-ILD progression.

Nur mit Berechtigung zugänglich

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM et al (2017) 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheum 69:35–45CrossRef

Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ 352:h6819PubMedPubMedCentralCrossRef

Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dorner T et al (2015) Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS task force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 54:2230–2238CrossRef

Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM (2018) Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren's syndrome. Clin Exp Rheumatol 36(Suppl 112):94–101PubMed

Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S (2016) Pulmonary manifestations of Sjogren's syndrome. Eur Respir Rev 25:110–123PubMedCrossRef

Shi JH, Liu HR, Xu WB, Feng RE, Zhang ZH, Tian XL, Zhu YJ (2009) Pulmonary manifestations of Sjogren's syndrome. Respiration 78:377–386PubMedCrossRef

Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Levesque H et al (2017) Interstitial lung disease in primary Sjogren's syndrome. Autoimmun Rev 16:48–54PubMedCrossRef

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558PubMedPubMedCentralCrossRef

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King te Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824PubMedPubMedCentralCrossRef

10.

American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664CrossRef

11.

Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y et al (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjogren syndrome patients: a case-control study. Medicine (Baltimore) 97:e11003CrossRef

12.

Wang Y, Hou Z, Qiu M, Ye Q (2018) Risk factors for primary Sjogren syndrome-associated interstitial lung disease. J Thorac Dis 10:2108–2117PubMedPubMedCentralCrossRef

13.

Margaritopoulos GA, Vasarmidi E, Jacob J, Wells AU, Antoniou KM (2015) Smoking and interstitial lung diseases. Eur Respir Rev 24:428–435PubMedCrossRef

14.

Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH (2018) Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest 154:394–408PubMedCrossRef

15.

Margaritopoulos GA, Harari S, Caminati A, Antoniou KM (2016) Smoking-related idiopathic interstitial pneumonia: a review. Respirology 21:57–64PubMedCrossRef

16.

Madan R, Matalon S, Vivero M (2016) Spectrum of smoking-related lung diseases: imaging review and update. J Thorac Imaging 31:78–91PubMedCrossRef

17.

Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C (2017) Prevalence and characterization of non-sicca onset primary Sjogren syndrome with interstitial lung involvement. Clin Rheumatol 36:1261–1268PubMedCrossRef

18.

Gao H, Zou YD, Zhang XW, He J, Zhang J, Sun Y, Li ZG (2018) Interstitial lung disease in non-sicca onset primary Sjogren's syndrome: a large-scale case-control study. Int J Rheum Dis 21:1423–1429PubMedCrossRef

19.

Goules AV, Kapsogeorgou EK, Tzioufas AG (2017) Insight into pathogenesis of Sjogren's syndrome: dissection on autoimmune infiltrates and epithelial cells. Clin Immunol 182:30–40PubMedCrossRef

20.

Mariette X, Criswell LA (2018) Primary Sjogren's syndrome. N Engl J Med 378:931–939PubMedCrossRef

21.

Rischmueller M, Tieu J, Lester S (2016) Primary Sjogren's syndrome. Best Pract Res Clin Rheumatol 30:189–220PubMedCrossRef

22.

Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, EULAR Sjögren's Task Force (2010) EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 69:1103–1109PubMedCrossRef

23.

Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, Gottenberg JE, Theander E, Tzioufas A, de Vita S, Ramos-Casals M, Dörner T, Quartuccio L, Ravaud P, Mariette X, EULAR Sjögren Task Force (2016) Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 75:1945–1950PubMedCrossRef

24.

Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T, Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups (2012) American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's international collaborative clinical Alliance cohort. Arthritis Care Res (Hoboken) 64:475–487CrossRef

25.

Baer AN, McAdams DeMarco M, Shiboski SC, Lam MY, Challacombe S, Daniels TE, Dong Y, Greenspan JS, Kirkham BW, Lanfranchi HE, Schiødt M, Srinivasan M, Umehara H, Vivino FB, Vollenweider CF, Zhao Y, Criswell LA, Shiboski CH, Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups (2015) The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren's syndrome. Ann Rheum Dis 74:1557–1561PubMedPubMedCentralCrossRef

26.

Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 10:509–513PubMedCrossRef

27.

Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M et al (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14:R50PubMedPubMedCentralCrossRef

28.

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Cohort Study (ASCS), Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33:S131–S135PubMed

29.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study Group (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988–995PubMedCrossRef

30.

Gunnarsson R, El-Hage F, Aalokken TM, Reiseter S, Lund MB, Garen T et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55:103–108CrossRef

31.

La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F (2006) In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39:249–253PubMedCrossRef

32.

Lee AYS (2017) A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int 37:1323–1333PubMedCrossRef

33.

American Thoracic S, European Respiratory S (2002) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med 165:277–304CrossRef

34.

Suda T (2015) Up-to-date information on rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med 9:155–162PubMed

35.

Migita K, Arai T, Jiuchi Y, Izumi Y, Iwanaga N, Kawahara C et al (2014) Predictors of mortality in patients with interstitial lung disease treated with corticosteroids: results from a cohort study. Medicine (Baltimore) 93:e175PubMedPubMedCentralCrossRef

36.

Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Fukuda Y, Yanagawa N et al (2013) Prognostic factors in interstitial lung disease associated with primary Sjogren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 8:e73774PubMedPubMedCentralCrossRef

37.

Chung JH, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, McKean D, Brown KK, Fingerlin TE, Schwarz MI, Schwartz DA, Lynch DA (2015) CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 147:450–459PubMedCrossRef

Titel: Characteristics of patients with primary Sjögren’s syndrome associated interstitial lung disease and relevant features of disease progression
verfasst von: Ting Zhang
Fangfang Yuan
Li Xu
Wenjia Sun
Lei Liu
Jing Xue
Publikationsdatum: 05.01.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 5/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04906-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials

The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review

Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab

A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease

Mortality of Chinese patients with polymyositis and dermatomyositis